FITC Anti-MEK4/MKK4 (phospho S257) antibody [SEK1MKK4S257-C5],Abcam,AB278655

What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

Flow Cyt

Conjugate

FITC

Platform ID

BAB869228301

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameFITC Anti-MEK4/MKK4 (phospho S257) antibody [SEK1MKK4S257-C5]
Cat. No.AB278655
HostRabbit
IsotypeIgG
ReactivityHuman
ConjugationFITC
ApplicationFlow Cyt
ClonalityMonoclonal
Clone NumberSEK1MKK4S257-C5
ImmunogenSynthetic Peptide within Human MAP2K4 phospho S257. The exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A/G
Appearance/FormLiquid
ShippingBlue Ice
FormulationPreservative: 0.09% Sodium azide Constituents: PBS, 0.2% BSA
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The phosphorylation of the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK activation at least in response to pro-inflammatory cytokines, while other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylate JNKs. MAP2K4 is required for maintaining peripheral lymphoid homeostasis. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7 exclusively activates JNKs, MAP2K4/MKK4 additionally activates the p38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14. See full target information MAP2K4 phospho S257

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.